Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 2, 2012, Pages 257-264

  Holman, Peter R ^a   Costello, Caitlin ^a   deMagalhaes Silverman, Margarida ^b   Corringham, Sue ^a   Castro, Januario ^a   Ball, Edward D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Autologous stem cell transplantation; Idiotype vaccination; Immunotherapy; Non Hodgkin lymphoma

Indexed keywords

IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; IMMUNE RESPONSE; MALE; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PILOT STUDY; PROGRESSION FREE SURVIVAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMOCYANIN; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PILOT PROJECTS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VACCINATION;

EID: 84855615963     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.06.011     Document Type: Article

References (57)

1. Khouri I.F., Romaguera J., Kantarjian H., et al. Hyper-CVAD andhigh-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.
2. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
3. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003, 21:3918-3927.
4. Mills W., Chopra R., McMillan A., Pearce R., Linch D.C., Goldstone A.H. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clinical Oncol 1995, 13:588-595.
5. Hsu F.J., Caspar C.B., Czerwinski D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997, 89:3129-3135.
6. Weng W.K., Czerwinski D., Timmerman J., Hsu F.J., Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004, 22:4717-4724.
7. Ai W.Z., Tibshirani R., Taidi B., Czerwinski D., Levy R. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 2009, 113:5743-5746.
8. Bendandi M., Gocke C.D., Kobrin C.B., et al. Complete molecularremissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171-1177.
9. Campbell M.J., Esserman L., Byars N.E., Allison A.C., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990, 145:1029-1036.
10. Campbell M.J., Esserman L., Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol 1988, 141:3227-3233.
11. Tao M.H., Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993, 362:755-758.
12. Miller R.A., Maloney D.G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. NEngl J Med 1982, 306:517-522.
13. Meeker T.C., Lowder J., Maloney D.G., et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985, 65:1349-1363.
14. Kwak L.W., Campbell M.J., Czerwinski D.K., Hart S., Miller R.A., Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992, 327:1209-1215.
15. Hsu F.J., Kwak L., Campbell M., et al. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann N Y Acad Sci 1993, 690:385-387.
16. Redfern C.H. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 2006, 24:3107-3112.
17. Koc O.N., Redfern C., Wiernik P.H., et al. Active immunotherapy with FavId(R) (Id/KLH) following rituximab induction: long-term follow-up of response rate improvement (RRI) and disease progression in follicular lymphoma patients (pts). Blood 2006, 108.
18. Koc O.N., Redfern C., Wiernik P.H., Rosenfelt F., Winter J.N. Continued late conversion to complete remission (CR/CRu) and durability of remission (DUR) in pts with B-cell follicular lymphoma (FL) treated with rituximab followed by mitumprotimut-T (Id-KLH, FavID) active immunotherapy. Blood 2007, 110.
19. Koc O.N., Redfern C., Wiernik P.H., et al. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother 2010, 33:178-184.
20. Schuster S., Neelapu S., Nichols C., et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission; phase III clinical trial results. J Clin Oncol 2009, 27(18 suppl):2.
21. Davis T.A., Hsu F.J., Caspar C.B., et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant 2001, 7:517-522.
22. Banks P.M., Chan J., Cleary M.L., et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992, 16:637-640.
23. Zucca E., Stein H., Coiffier B. European Lymphoma Task Force (ELTF): report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 1994, 5:507-511.
24. Zucca E., Roggero E., Pinotti G., et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6:257-262.
25. Bosch F., Lopez-Guillermo A., Campo E., et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567-575.
26. Khouri I.F., Romaguera J., Kantarjian H., et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.
27. Khouri I.F., Saliba R.M., Okoroji G.J., Acholonu S.A., Champlin R.E. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003, 98:2630-2635.
28. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with invivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
29. Gianni A.M., Magni M., Martelli M., et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and invivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003, 102:749-755.
30. Mangel J., Leitch H.A., Connors J.M., et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004, 15:283-290.
31. Evens A.M., Winter J.N., Hou N., et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol 2008, 140:385-393.
32. Dreger P., Rieger M., Seyfarth B., et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007, 92:42-49.
33. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
34. Milpied N., Gaillard F., Moreau P., et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998, 22:645-650.
35. Vandenberghe E., Ruiz de Elvira C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:793-800.
36. Freedman A.S., Neuberg D., Gribben J.G., et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998, 16:13-18.
37. Freedman A., Neelapu S.S., Nichols C., et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009, 27:3036-3043.
38. Jones I., Morikawa Y. Baculovirus vectors for expression in insect cells. Curr Opin Biotechnol 1996, 7:512-516.
39. Kwak L.W., Young H.A., Pennington R.W., Weeks S.D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 1996, 93:10972-10977.
40. Kwak L.W., Campbell M., Levy R. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Cancer Detect Prev 1991, 15:323-325.
41. Kwak L.W., Campbell M.J., Zelenetz A.D., Levy R. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood 1990, 76:2411-2417.
42. Mackall C.L., Bare C.V., Granger L.A., Sharrow S.O., Titus J.A., Gress R.E. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996, 156:4609-4616.
43. Inoges S., Rodriguez-Calvillo M., Zabalegui N., et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006, 98:1292-1301.
44. Navarrete M.A., Heining-Mikesch K., Schuler F., et al. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood 2011, 117:1483-1491.
45. Levy R., Robertson M.J., Leonard J., Vose J.M., Denney D. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (ID) conjugated to KLH (ID-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin lymphoma (FNHL). Ann Oncol 2008, 19(Suppl4). abstract 057.
46. Pettengell R., Schmitz N., Gisselbrecht C., et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as invivo purging and to maintain remission following high-dose therapy. J Clin Oncol 2010, 28(Suppl 15). abstract 8005.
47. Leonard J., Vose J.M., Timmerman J.M., et al. Recombinant idiotype-KLH vaccination (MyVax™) following CHOP chemotherapy in mantle cell lymphoma. Blood 2003, 102(105a).
48. Wilson WH, Neelapu S, Rosenwald A, etal. Idiotype vaccine and dose-adjusted EPOCH-rituximab treatment in untreated mantle cell lymphoma: preliminary report on clinical outcome and analysis of immune response. In: American Society of Hematology 45th Annual Meeting and Exposition; 2003 December 6-9; San Diego, CA. Abstract 358.
49. Neelapu S.S., Kwak L.W., Kobrin C.B., et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005, 11:986-991.
50. Holman P., Corringham S., Bashey A., et al. Early and robust immune responses to idiotype (Id) vaccination occur in mantle cell lymphome (MCL) and indolent lymphoma (IL) patients following autologous stem cell transplantation. Blood 2003, 102. abstract #3345.
51. Dreger P., Martin S., Kuse R., et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46patients. Hematol J 2000, 1:87-94.
52. Freedman A.S., Neuberg D., Gribben J.G., et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998, 16:13-18.
53. Ganti A.K., Bierman P.J., Lynch J.C., Bociek R.G., Vose J.M., Armitage J.O. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005, 16:618-624.
54. Haas R., Brittinger G., Meusers P., et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996, 10:1975-1979.
55. Kroger N., Hoffknecht M., Dreger P., et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998, 21:55-57.
56. Stewart D.A., Vose J.M., Weisenburger D.D., et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Ooncol 1995, 6:263-266.
57. Geisler C., Kolstad A., Laurell A., et al. Nordic MCL2 trial of 1st-line intensive immunochemotherapy and autologous stem cell transplantation in mantle cell lymphoma: still encouraging results after median 5 1/2 years observation time. Biol Blood Marrow Transplant 2011, 17(Suppl 2):S196.